# A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01193179` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01193179](<https://clinicaltrials.gov/study/NCT01193179>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01193179

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 450 participants.

## Technical summary

Registry record NCT01193179. Allocation not applicable; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT01193179, source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01193179, source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)
- Primary completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01193179, source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)
- Completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01193179, source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01193179, source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01193179-2014-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes
- Condition: Diabetes, Type 2
- Intervention (Drug): OPC-262
- Lead sponsor: Kyowa Kirin Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Kyowa Kirin Co., Ltd. (`cardio:org-kyowa-kirin-co-ltd`)

## Provenance

Content hash: cf4a28968c3cc21992fa9355b0d44f7d0f1a3f07effa72980b2fbebea8072253
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
